Faculty Index   Dr. Becich   Dr. D. Becker   Dr. J. Becker   Dr. Billiar   Dr. Blair   Dr. Bostwick   Dr. Bowser   Dr. Chaillet   Dr. Chang   Dr. Cheng   Dr. Chu   Dr. Clemens   Dr. DeFrances   Dr. Delude   Dr. Demetris   Dr. Dong   Dr. Donnenberg   Dr. Gandhi   Dr. Giannoukakis   Dr. Gnarra   Dr. Grandis   Dr. Hebda   Dr. Huard   Dr. Kaminski   Dr. Katyal   Dr. Kelavkar   Dr. Klunk   Dr. Kulich   Dr. Lagasse   Dr. Latimer   Dr. Luyuan Li   Dr. Yong Li   Dr. Youhua Liu   Dr. Lokshin   Dr. Luo   Dr. Lyons-Weiler   Dr. Monga   Dr. Mars   Dr. Michalopoulos   Dr. Ochoa   Dr. O'Keefe   Dr. Oltvai   Dr. Oury   Dr. Pflug   Dr. Piganelli   Dr. Saunders   Dr. Shapiro   Dr. Stolz   Dr. Strom   Dr. Surti   Dr. Vodovotz   Dr. Wang   Dr. Wells   Dr. Wenzel   Dr. Wiley   Dr. Wu   Dr. Yin   Dr. Zarnegar

Jianhua Luo, Associate Professor MD, Guangzhou Medical Institute, Canton, China, 1982 PhD, University of Maryland at Baltimore, MD, USA, 1992 Email:  luojh@pitt.edu Completion of human genome sequencing laid down the foundation for genome-wide analysis of gene expression in human malignancies. In order to understand the pathogenesis of prostate cancer, it is necessary to identify which set of the estimated 30,000 to 40,000 genes in the human genome involving in the development of the disease. Application of high throughput, quantitative analysis of gene expression in human cancer samples appears to be the most logical and conventional way to obtain information of gene expression alterations in human cancer, and help to identify critical genetic event triggering the irreversible process of malignancy. In the past three years, we have been utilizing two important technologies to study genetic alterations in prostate cancer, i.e. Affymetrix's oligo chip array and differential subtraction chain developed from this laboratory. Despite high incidences of prostate cancer among men in the United States, only a small fraction of prostate cancer develops life-threatening conditions. Recently, using differential subtraction chain, we identified two novel genes whose alteration might be associated with progression of prostate cancer. Currently, we are focusing on investigating physiological role of one of these genes, myopodin, and its mechanism that mediates metastasis suppression activity. By performing large scale Affymetrix chip analysis, we identify a set of genes whose expression alterations dictate the aggressive behavior of prostate cancer. Preliminary random blind test suggest that this set of genes is a fairly reliable outcome predictor. Larger clinical test is underway to determine possible clinical usage of this gene profile predictor. Recent Publication Yan P. Yu, Guoying Yu, George Tseng, Kathleen Cieply, Joel Nelson, Marie Defrances, Reza Zarnegar, George Michalopoulos and Jian-Hua Luo (2007). Glutathione Peroxidase 3, Deleted or Methylated In Prostate Cancer, Suppresses Prostate Cancer Growth and Metastasis. Cancer Research, in press. Baoguo Ren, Yan P. Yu, George C. Tseng, Chuanyue Wu, Ka Chen, Uma N. Rao, Joel Nelson, George K. Michalopoulos and Jian-Hua Luo (2007). Analysis of Integrin ¦Á7 Mutations in Prostate Cancer, Liver Cancer, Glioblastoma Multiforme, and Leiomyosarcoma. Journal of National Cancer Institute, 99, 868-880. Craig, F.E., Johnson, L.R., Harvey, S.A.K., Nalesnik, M.A., Luo, J.H., Bhattacharya, S.D., and Swerdlow, S.H. (2007). Gene Expression Profiling of Epstain-Bar Virus-Positive and Negative Monomorphic B-Cell Post-transplant Lymphoproliferative Disorders. Diagnostic Molecular Pathology, in press Shirish Paranjpe, William C. Bowen, Aaron W. Bell, Kari Nejak-Bowen, Jian-Hua Luo and George K. Michalopoulos (2007). Cell cycle effects caused by inhibition of HGF and its receptor c-met in regenerating rat livers by RNA interference. Hepatology 45, 1471-1477. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, Dacic S. (2007). Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 67(5):2345-50. Yingjian Li, Junwei Yang, Jian-Hua Luo, Shoukat Dedhar and Youhua Liu (2007). Tubular epithelial cells dedifferentiation is driven by helix-loop-helix transcriptional inhibitor Id1. Journal of American Society of Nephrology 18, 449-60. Jian-Hua Luo, Baoguo Ren, Sergei Keryanov, George C. Tseng, Uma N.M. Rao, Satdarshan P. Monga, Steven Strom, Anthony J. Demetris, Michael Nalesnik, Yan P. Yu, Sarangarajan Ranganathan and George K. Michalopoulos (2006). Transcriptomic and Genomic analysis of Human Hepatocellular Carcinomas and Hepatoblastomas. Hepatology 44, 1012-1024. Yan Ping Yu and Jian-Hua Luo (2006). Myopodin Mediated Suppression of Prostate Cancer Cell Migration Involves Interaction with Zyxin. Cancer Research, 66, 7414-7419. Yan Ping Yu, George C. Tseng and Jian-Hua Luo (2006). Inactivation of Myopodin Expression Is Associated with Prostate Cancer Relapse. Urology 68, 578-82. Guoying Yu, George C. Tseng, Yan Ping Yu, Tim Gavel, Joel Nelson, Alan Wells, George Michalopoulos, Demetrius Kokkinakis and Jian-Hua Luo (2006). CSR1 Suppresses Tumor Growth and Metastasis of Prostate Cancer. American Journal of Pathology 168, 597-607. Baoguo Ren, Guoying Yu, George C. Tseng, Kathleen Cieply, Timothy Gavel, Joel Nelson, George Michalopoulos, Yan Ping Yu and Jian-Hua Luo (2006). MCM7 Amplification and Overexpression Are Associated with Prostate Cancer Progression. Oncogene 25, 1090-1098.